REG - Cambridge Cognition - Total Voting Rights and Block Listing Return

Cambridge Cognition HoldingsAnnouncement

02/04/2024 16:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240402:nRSB0298Ja&default-theme=true

RNS Number : 0298J  Cambridge Cognition Holdings PLC  02 April 2024

2 April 2024

 

Cambridge Cognition Holdings plc

 

("Cambridge Cognition", the "Company" or the "Group")

 

Total Voting Rights and Block Listing Return

 

 

Cambridge Cognition (AIM: COG), which develops and markets digital solutions
to assess brain health, announces that pursuant to its block admission
facility, details of which were announced on 21 March 2023, it has recently
issued 189,263 new ordinary shares in the Company in satisfaction of the
exercise of employee share options. Accordingly, as at 31 March 2024 the
Company has 35,149,372 ordinary shares in issue.

 

There are no shares held in treasury therefore the total number of voting
rights in the Company is 35,149372. This figure may be used by shareholders as
the denominator for the calculation by which they will determine if they are
required to notify their interest in, or a change to their interest in
Cambridge Cognition under the FCA's Disclosure and Transparency Rules.

 

Block Listing Return

 

The Company also makes the following notification pursuant to AIM Rule 29
and Schedule Six of the AIM Rules for Companies, regarding its existing block
listings:

 

 

 Name of applicant:                                                                Cambridge Cognition Holdings plc
 Name of scheme:                                                                   Share Options
 Period of return:                        From:                                    1 October 2023               To:                          31 March 2024
 Number and class of share(s) (amount of stock / debt securities) originally       1,000,000 ordinary shares of £0.01 each in the Company admitted to trading on
 listed and the date of admission:                                                 23 March 2023
 Balance of unallotted securities under scheme(s) from previous return:            762,855 ordinary shares
 Plus:  The amount by which the block scheme(s) has been increased since the       Nil
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period:        296,539 ordinary shares
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        466,316 ordinary shares

 

 Name of contact:              Stephen Symonds
 Telephone number of contact:  +44 (0)1223 810700

 

 

Enquiries:

 

 Cambridge Cognition Holdings plc                         Tel: 012 2381 0700

 Matthew Stork, Chief Executive Officer                   press@camcog.com (mailto:press@camcog.com)

 Stephen Symonds, Chief Financial Officer

 Panmure Gordon (UK) Limited (NOMAD and Joint Broker)     Tel: 020 7886 2968

 Freddy Crossley / Emma Earl                              (Corporate Finance)

 Rupert Dearden                                           (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)                   Tel: 020 3903 7715

 David Poutney / James Serjeant

 Hudson Sandler (Financial PR and IR)                     Tel: 020 7796 4133

 Dan de Belder / Hattie Dreyfus                           cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)

 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRSSWFIEELSEFL